CTI Biopharma (Formerly Cell Therapeutics)
CTI BioPharma | Seeking to Bring New Options to Patients with Blood Cancers.
Launch date
Employees
Market cap
AUD1.9b
Enterprise valuation
AUD1.8b (Public information from Jul 2023)
Share price
$9.09 CTIC
Seattle Washington (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 22.9m | 23.9m | 3.0m | 49.0m | 20.9m | 49.0m |
| % growth | - | - | 5 % | (87 %) | 1513 % | (57 %) | 135 % |
| EBITDA | - | (34.6m) | (24.6m) | (34.5m) | (46.3m) | (86.8m) | (69.9m) |
| % EBITDA margin | - | (151 %) | (103 %) | (1135 %) | (94 %) | (415 %) | (143 %) |
| Profit | - | (37.0m) | (26.7m) | (36.4m) | (47.7m) | (89.0m) | (84.5m) |
| % profit margin | - | (162 %) | (112 %) | (1196 %) | (97 %) | (426 %) | (172 %) |
| EV / revenue | - | 4.6x | 1.6x | 27.2x | 4.5x | 9.5x | 4.2x |
| EV / EBITDA | - | -3.0x | -1.6x | -2.4x | -4.8x | -2.3x | -3.0x |
| R&D budget | 62.0m | 29.9m | 33.2m | 21.9m | 23.6m | 35.6m | 33.5m |
| R&D % of revenue | - | 131 % | 139 % | 721 % | 48 % | 170 % | 68 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $30.0m | Post IPO Equity | |
| N/A | $4.1m | Post IPO Equity | |
| N/A | $25.0m | Post IPO Equity | |
$5.0m | Post IPO Debt | ||
N/A | Post IPO Equity | ||
| N/A | $50.7m | Post IPO Equity | |
| N/A | $50.0m | Post IPO Debt | |
* | $1.7b Valuation: $1.7b 31.5x EV/LTM Revenues -22.1x EV/LTM EBITDA | Acquisition | |
| Total Funding | - | ||
Related Content
Recent News about CTI Biopharma (Formerly Cell Therapeutics)
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.